Drug Profile
JT 03
Alternative Names: JT-03Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator JYANT Technologies
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Chemokine CXCL13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis; Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 11 Aug 2016 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)